AKT1 and osteosarcoma: Besides direct inhibition of osteosarcoma cell growth and viability due to inhibition of ERK and Akt-signaling pathways, cabozantinib can affect the tumor microenvironment by reducing the production of receptor activator of nuclear factor-kB ligand (RANKL) by osteoblasts.